Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | SVP,Clinical & Medical Affairs | March 09, 2023 | March 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date March 09, 2023 · Filed March 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2033-03-09 | Direct | 400,000 |
Reported balance
After 2023-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-09 · Grant · Acquired 400,000 · Balance 400,000 F1: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2023 Filed Mar 11, 2023 00:06 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-23-007310 · ownership.xml · derivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 13,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-004895 · ownership.xml · derivative · entry 3 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,061 Underlying: Common Shares · 13,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. F4 · derivative.expiration_date: The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 5,310 | $1.35 | $7,168.50 |
DisclosureSEC source: 0001493152-23-004895 · ownership.xml · nonDerivative · entry 2 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,710 F3 · shares: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 13,020 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 21:15 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 13,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-004895 · ownership.xml · nonDerivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F1 · price: Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis. F2 · balance_after: Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 10, 2022 Filed Mar 12, 2022 01:43 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001493152-22-006696 · ownership.xml · derivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Shares · 450,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:42 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantRestricted Stock Units · Derivative | 52,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004718 · ownership.xml · derivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,081 Underlying: Common Shares · 52,081 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share. F2 · derivative.exercise_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: Subject to continuous service, vests in four equal annual installments beginning on February 11, 2023. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,250 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · derivative · entry 11 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,750 Underlying: Common Shares · 9,250 shares Expires 2030-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 444,000 common shares of the issuer. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 28,445 | $2.44 | $69,405.80 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 7 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.42 to not more than $2.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 9,250 | $2.49 | $23,032.50 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 6 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,445 F2 · price: The 9,250 shares sold on 12/29/21, were all sold at a transaction price of $2.49. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 9,250 | $0.69 | $6,400.08 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 5 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 79,689 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · derivative · entry 10 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,811 Underlying: Common Shares · 79,689 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The reporting person was granted options on February 12, 2019, with an exercise price of $1.14 per share to purchase up to 112,500 common shares of the issuer. One quarter of the options vested and became exercisable on February 12, 2020, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 236,899 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · derivative · entry 9 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,301 Underlying: Common Shares · 236,899 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted options on February 11, 2018, with an exercise price of $2.11 per share to purchase up to 247,200 common shares of the issuer. One quarter of the options vested and became exercisable on February 11, 2019, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · derivative · entry 8 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,000 Underlying: Common Shares · 185,000 shares Expires 2030-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 444,000 common shares of the issuer. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 501,588 | $2.45 | $1,228,890.60 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 4 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,445 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.40 to not more than $2.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 79,689 | $1.14 | $90,845.46 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 3 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 236,899 | $2.11 | $499,856.89 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 2 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:20 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 185,000 | $0.69 | $128,001.50 |
DisclosureSEC source: 0001493152-21-032897 · ownership.xml · nonDerivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 419,500 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001493152-21-006270 · ownership.xml · derivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,500 Underlying: Common Shares · 419,500 shares Expires 2031-03-15 F1 · derivative.exercise_date: One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 444,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001493152-20-004350 · ownership.xml · derivative · entry 1 Hogge Gary S. · CIK 0001771711 · SVP,Clinical & Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,000 Underlying: Common Shares · 444,000 shares Expires 2030-03-17 F1 · derivative.exercise_date: One quarter of the options shall vest on March 17, 2021 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.